賽托瑞醫療 CYTX 深 滬
已收盤 08-30 16:00:00 美东时间
0.2077
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 總市值 376.46万
- 52周最高 14062.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3825.00
- 委 比 0.00%
- 總股本 1812.50万
- 歷史最高 13865625.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3825.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Plus Therapeutics Subsidiary Gets Enrolled In Medicare Program, Receives Provider Transaction Access Number From Centers For Medicare & Medicaid Services
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-07 19:33
Why Is Plus Therapeutics Stock Gaining Friday?
Plus Therapeutics stock jumps after FDA grants Orphan Drug status to Reyobiq for pediatric brain cancer, boosting long-term outlook.
04-11 02:12
Plus Therapeutics names Eric Daniels chief development officer to advance clinical pipeline
Plus Therapeutics names Eric Daniels chief development officer to advance clinical pipeline Plus Therapeutics named Eric J. Daniels chief development officer, effective April 20, 2026. Daniels most recently served as chief development officer at Kiora Pharmaceuticals, overseeing clinical, preclinica
04-09 19:35
U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO
U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO April 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Union Pacific and XPO, on Tuesday. HIGHLIGHTS * Centerspace CSR.N : Piper Sandler raises to overw
04-07 16:04
CNSide Diagnostics Signs New Payer Coverage Agreement With Highmark To Offer Reimbursement For Its CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay For Patients With Metastatic Central Nervous System Cancers
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today announces a new payer coverage agreement with Highmark, effective April 1,
04-02 19:32
D. Boral Capital Downgrades Plus Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Plus Therapeutics (NASDAQ:PSTV) from Buy to Hold.
03-31 22:56
Plus Therapeutics announces 1-for-25 reverse stock split
Plus Therapeutics (PSTV) on Tuesday announced a reverse stock split of its shares of common stock at a ratio of 1-for-25. The reverse stock split will become effective on April 2, 2026, and the compan...
03-31 19:53
Plus Therapeutics Announces 1-For-25 Reverse Stock Split, Effective April 2
Plus Therapeutics, Inc. (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the
03-31 19:32
Plus Therapeutics Announces Reverse Stock Split
Plus Therapeutics, Inc. announced that its Board of Directors has approved a 1-for-25 reverse stock split to increase the per share trading price of its common stock to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 2, 2026. The common stock will continue to trade under the symbol “PSTV” with a new CUSIP numbe...
03-31 11:30
Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience
Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience Plus Therapeutics appointed Ron Andrews to its Board of Directors. Andrews has more than 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Abbo
03-26 19:32
